GlassScriptPhysician profile
Sarah White
NPI 1053638304
$11,898.04
in general payments reported to CMS, 2019-2025
37 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,817 · 2022: $2,100 · 2023: $3,146 · 2024: $2,099 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,926 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,925.82 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,192.47 | 2021-2025 | Krystexxa, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,443.43 | 2021-2025 | |
| Pfizer INC. | $1,034.75 | 2021-2025 | |
| Ucb, INC. | $992.97 | 2021-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $941.03 | 2021-2025 | Acthar |
| Janssen Biotech, INC. | $937.93 | 2021-2025 | Tremfya, Simponi Aria, Acclarent Aera |
| Lilly USA, LLC | $686.73 | 2021-2025 | Taltz |
| Radius Health, INC. | $654.57 | 2021-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $346.97 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $296.50 | 2023-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $292.13 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $256.55 | 2021-2023 | Benlysta |
| Genentech USA, INC. | $246.00 | 2021-2025 | Actemra, Rituxan, Gazyva |
| Aurinia Pharma U.S., INC. | $223.88 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $199.14 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $196.92 | 2021 | |
| Ferring Pharmaceuticals INC. | $123.65 | 2021-2023 | Euflexxa |
| Fresenius Kabi USA, LLC | $111.40 | 2023-2025 | Idacio, Tyenne |
| Actelion Pharmaceuticals US, INC. | $103.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.11 | 2023-2025 | Cyltezo, Ofev |
| Abbvie INC. | $85.69 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $61.37 | 2023-2024 | Simlandi, Truxima |
| Organon LLC | $41.76 | 2023-2025 | Hadlima |
| Genzyme Corporation | $39.84 | 2021 | |
| Astellas Pharma US INC | $38.73 | 2025 | Vyloy |
| Nevro Corp. | $30.57 | 2023 | Senza |
| Sobi, INC | $29.72 | 2025 | |
| Almatica Pharma LLC | $28.37 | 2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $22.21 | 2024 | Crysvita |
| Depuy Synthes Sales INC. | $20.41 | 2025 | Monovisc |
| Sandoz INC. | $19.92 | 2023 | Hyrimoz |
| Celltrion USA INC. | $18.76 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $17.85 | 2023 | Libtayo |
| Pacira Pharmaceuticals Incorporated | $16.97 | 2025 | Zilretta |
| Invivyd INC | $15.38 | 2025 | Pemgarda |
| Scilex Pharmaceuticals INC. | $14.30 | 2024 | |
| Shield Therapeutics INC | $13.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.